Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Paul Anthony Ellis"'
Autor:
Edith A. Perez, Sanne Lysbet de Haas, Wolfgang Eiermann, Carlos H. Barrios, Masakazu Toi, Young-Hyuck Im, Pier Franco Conte, Miguel Martin, Tadeusz Pienkowski, Xavier B. Pivot, Howard A. Burris, Sven Stanzel, Monika Patre, Paul Anthony Ellis
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-14 (2019)
Abstract Background The phase III EMILIA and TH3RESA trials demonstrated clinical benefits of trastuzumab emtansine (T-DM1) therapy in patients with previously treated HER2-positive metastatic breast cancer (MBC). Data from these and other trials sho
Externí odkaz:
https://doaj.org/article/09e852dddd5a43cfa17d3f82a5431f82
Autor:
Edith A. Perez, Sanne Lysbet de Haas, Wolfgang Eiermann, Carlos H. Barrios, Masakazu Toi, Young-Hyuck Im, Pier Franco Conte, Miguel Martin, Tadeusz Pienkowski, Xavier B. Pivot, Howard A. Burris, Sven Stanzel, Monika Patre, Paul Anthony Ellis
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-2 (2019)
Following publication of the original article [1], the authors reported the following errors in the article.
Externí odkaz:
https://doaj.org/article/690a5325d92f4fad952802d4d744779b
Autor:
C. Lambertini, Tadeusz Pienkowski, Silke Hoersch, Monika Patre, Howard A. Burris, Pierfranco Conte, Wolfgang Eiermann, Sanne de Haas, Young Hyuck Im, Miguel Martin, Xavier Pivot, Edith A. Perez, Masakazu Toi, Carlos Barrios, Paul Anthony Ellis
Publikováno v:
Cancer Research. 80:PD5-11
Introduction: Although HER2+ breast cancer (BC) is considered a moderately immunogenic tumor, several studies have shown a role of pre-existing immunity associated with favorable long-term prognosis and better response to treatment. In this study, we
Autor:
Rachel Wuerstlein, Margarita Donica, Antonio Anton, Jacques Bonneterre, Suzette Delaloge, N Quenel-Tueux, Natsumi Irahara, Nicolas Lindegger, Sabine C. Linn, Carlos H. Barrios, Paul Anthony Ellis, Filippo Montemurro
Publikováno v:
European Journal of Cancer. 109:92-102
Background Many patients with metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) are candidates for trastuzumab emtansine (T-DM1) treatment sometime in their disease history. KAMILLA evaluated safety of T-DM1 in pa
Autor:
I. Melero, G Lewis Phillips, Sandra M. Swain, Carlos H. Barrios, Hervé Bonnefoi, EP Winer, L. Gianni, SL de Haas, M. Toi, S-A. Im, Thomas Boulet, Charles M. Perou, Paul Anthony Ellis, Ian E. Krop, C. Lambertini, Nadia Harbeck, Chunyan Song, Julie R. Gralow, Otto Metzger, Fraser Symmans
Publikováno v:
Annals of Oncology. 32:S37-S38
Autor:
Filippo Montemurro, Rachel Wuerstlein, Suzette Delaloge, Simon Fear, Andhika Rachman, Claudia Pena-Murillo, Shusen Wang, Huiping Li, Haiying Liu, Xiaojia Wang, Carlos H. Barrios, Mawin Vongsaisuwon, Shao Zhi-min, Qingyuan Zhang, Paul Anthony Ellis, Antonio Antón Torres
Publikováno v:
Journal of Clinical Oncology. 39:1039-1039
1039 Background: KAMILLA is an open-label, single-arm, phase 3b safety study of T-DM1 in pts with HER2-positive advanced BC (NCT01702571). The treated (safety) population of KAMILLA comprises 2 cohorts: a larger global Cohort 1 (n=2002) and a smaller
Autor:
Masakazu Toi, Monika Patre, Howard A. Burris, Edith A. Perez, Miguel Martín, Tadeusz Pienkowski, Xavier Pivot, Jennifer A. Petersen, Carlos H. Barrios, Young-Hyuck Im, Wolfgang Eiermann, Pierfranco Conte, Silke Hoersch, Paul Anthony Ellis, Sanne de Haas
Background In the phase 3 MARIANNE trial, trastuzumab emtansine (T-DM1) with or without pertuzumab showed noninferior progression-free survival and better tolerability than trastuzumab plus a taxane (HT) for the first-line treatment of human epiderma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee058c3c727baa44f84b731e1ba595d9
http://hdl.handle.net/11577/3308749
http://hdl.handle.net/11577/3308749
Autor:
Luca Gianni, Zbigniew Nowecki, Seock-Ah Im, Thomas Boulet, Ian E. Krop, Michelino De Laurentiis, Julie Gralow, Nadia Harbeck, Haiying Liu, Peter Trask, Eric P. Winer, Young-Hyuck Im, Chunyan Song, Paul Anthony Ellis, Masakazu Toi, Sandra M. Swain, Harrison Macharia, Jigna Shah, Hervé Bonnefoi, Carlos Barrios
Publikováno v:
Journal of Clinical Oncology. 38:500-500
500 Background: The standard of care for HER2-positive EBC is chemotherapy plus one year of HER2-directed therapy. However, recurrence—particularly in high-risk populations—remains a problem, as does systemic chemotherapy-associated toxicity. In
Autor:
Masakazu Toi, Sanne de Haas, Paul Anthony Ellis, Edith A. Perez, Tadeusz Pienkowski, Sven Stanzel, Wolfgang Eiermann, Miguel Martin, Pierfranco Conte, Monika Patre, Carlos H. Barrios, Young Hyuck Im, Howard A. Burris, Xavier Pivot
Publikováno v:
BMC Cancer
BMC Cancer, Vol 19, Iss 1, Pp 1-14 (2019)
BMC Cancer, Vol 19, Iss 1, Pp 1-14 (2019)
Background: The phase III EMILIA and TH3RESA trials demonstrated clinical benefits of trastuzumab emtansine (T-DM1) therapy in patients with previously treated HER2-positive metastatic breast cancer (MBC). Data from these and other trials showed that
Autor:
Young-Hyuck Im, Paul Anthony Ellis, Xavier Pivot, Edith A. Perez, Silke Hoersch, Wolfgang Eiermann, Miguel Martin, Tadeusz Pienkowski, Monika Patre, Howard A. Burris, Pierfranco Conte, Masakazu Toi, Carlos H. Barrios
Publikováno v:
Journal of Clinical Oncology. 35:1003-1003
1003 Background: In MARIANNE (NCT01120184), patients with HER2-positive advanced breast cancer were randomized to trastuzumab + docetaxel or paclitaxel (HT; n=365), T-DM1 + placebo (T-DM1; n=367), or T-DM1 + P (T-DM1 + P; n=363) as first-line therapy